What is Mabt?
Mid-Atlantic BioTherapeutics (Mabt), founded in 2011, is a biotechnology firm dedicated to pioneering novel treatments for challenging neurological and infectious diseases, including Alzheimer's, Parkinson's, and ALS. The company recently bolstered its oncology pipeline through the acquisition of XPose Therapeutics, sharpening its focus on breakthrough therapies for difficult-to-treat cancers. Mabt integrates biotechnology with artificial intelligence to create advanced therapeutic solutions, addressing critical unmet medical needs and striving to enhance patient outcomes through compassionate innovation.
How much funding has Mabt raised?
Mabt has raised a total of $50M across 1 funding round:
Other Financing Round
$50M
Other Financing Round (2025): $50M with participation from Legend Innovators
Key Investors in Mabt
Legend Innovators
Legend Innovators is a business advisory firm specializing in startup mentoring and fund-raising services. Their focus on empowering businesses through innovative strategies aligns with Mabt's mission to advance novel therapies.
What's next for Mabt?
The recent major strategic investment, amounting to $50M, positions Mabt for significant growth and pipeline advancement. This capital injection is expected to fuel further research and development, potentially enabling the company to accelerate clinical trials and expand its therapeutic offerings in oncology, neurology, and infectious diseases. Mabt's strategic use of AI in drug discovery, combined with its recent acquisition, suggests a forward-looking approach to tackling complex health challenges and improving patient lives.
See full Mabt company page
